Company profile: Sania Therapeutics
1.1 - Company Overview
Company description
- Provider of precision genetic neuromodulation therapies for nervous system disorders, using chemogenetics to safely and accurately alter neuronal activity and stabilize faulty electrical signaling. Offers AAV-based delivery systems with proprietary human-centric platforms to target specific cells. Lead program addresses hyperexcitable motor dysfunctions, such as spasticity, by targeting neural subtypes for long-term therapeutic benefit.
Products and services
- AAV-Based Delivery System: A proprietary platform utilizing adeno-associated viral vectors and human-centric technology to deliver genetic material precisely to specific cells, enabling targeted delivery within defined cellular populations
- Precision Genetic Neuromodulation: A precision-targeted therapeutic system that focuses on dysfunctional neurons and regulates their electrical activity to deliver long-term therapeutic benefit within affected neural populations
- Hyperexcitable Motor Dysfunction Program: A subtype-targeted program addressing hyperexcitable motor dysfunctions, including spasticity, by targeting specific neural subtypes to enable precision neuromodulation of pathological motor activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sania Therapeutics
Prestwick Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic pharmaceutical drugs for chronic central nervous system diseases, offering products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea. Founded in 2002 and based in Washington, District of Columbia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prestwick Pharmaceuticals company profile →
Athira Pharma
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology and pharmaceutical drug development focused on neurodegenerative diseases. Develops small-molecule therapies including fosgonimeton, which enhances hepatocyte growth factor/MET activity for conditions like Alzheimer’s and Parkinson’s, and ATH-1105, a positive modulator of the neurotrophic HGF system for ALS. Conducts clinical trials to assess safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athira Pharma company profile →
Aruna Bio
HQ: United States
Website
- Description: Provider of neural exosome-based therapies for central nervous system and neurodegenerative disorders; developer of AB126, a therapeutic neural cell-derived exosome that crosses the blood-brain barrier to reduce neuro-inflammation, promote neuro-protection, and stimulate neuro-regeneration, plus a CNS therapeutic platform and pipeline; also conducts research in stem cells, neural stem cells, and drug toxicity assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aruna Bio company profile →
Naurex
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for depression and other CNS disorders, based on a novel mechanism to modulate the N-methyl-D-aspartic acid receptor (NMDAR); developing novel chemical drug classes called glycine-site functional partial agonists (GFPAs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Naurex company profile →
Sequent Medical
HQ: United States
Website
- Description: Provider of innovative catheter-based neurovascular technologies, including proprietary Microbraid™ technology used to create the WEB™ Aneurysm Embolization System for the treatment of neurovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequent Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sania Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sania Therapeutics
2.2 - Growth funds investing in similar companies to Sania Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sania Therapeutics
4.2 - Public trading comparable groups for Sania Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →